AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 192 min read$LLY

Eli Lilly (LLY) Reports Positive Phase 3 SHINE-2 Trial Results f

Eli Lilly (LLY) reported positive Phase 3 SHINE-2 trial results for Omvoh in pediatric ulcerative colitis, showing 81% clinical response and 50% remission rates. The company's GF Value™ suggests a 20.4% undervaluation, with a GF Score™ of 96/100. Insider selling totaled $2.66 billion over 12 months, while 25 gurus hold the stock with balanced activity. LLY's P/E ratio is 42.71x, below its 5-year median of 53.19x.

Original reporting
gurufocus.com
Published Oct 19, 2026, 9:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 10:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$LLY
Bullish
high confidence
Mentioned
$LLY
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

The SHINE-2 data could expand the drug's label, adding a new revenue stream and supporting the stock's valuation.

02

Market read

First‑time disclosure of pivotal trial data for a pediatric indication, likely to move the stock.

03

What to watch

Regulatory approval timelines and reimbursement uncertainty may temper upside.

Relevance 7/10Novelty 9/10Timing: today

Background

Eli Lilly's pipeline includes several high‑growth products; Omvoh is its IL‑23p19 inhibitor.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly announced positive Phase 3 SHINE-2 trial results for Omvoh in pediatric ulcerative colitis.

Expected impact

upward pressure as investors price in the potential new indication.

Evidence & confidence

Phase 3 data for a first‑in‑class IL‑23p19 inhibitor in a new patient group is material and not yet priced in.

Market effects

Sector

Boosts sentiment for immunology and IBD drug developers.

Regional

Positive for US pharma equities.

Global

Potential worldwide demand for pediatric ulcerative colitis therapy.

Counterpoint

What could challenge this read

Recent insider selling could signal concerns about valuation or upcoming risks.

Key entities

  • company
    Eli Lilly and Co

    Pharmaceutical company reporting the trial results.

Read at source← All news

StoryEli Lilly reports 81% response and 50% remission in pediatric ulcerative colitis trial

Also covered by

1 outlet

Related articles

OCT 19
$LLYMed

Your Questions Answered: Foundayo’s EU Panel Backing, Enspryng for TED, Gilead’s Masked TCE Bet, FDA’s Rare Disease Overhaul, and More

Eli Lilly's Foundayo received a positive CHMP opinion for EU marketing authorization for weight management and type 2 diabetes. Roche's Enspryng gained FDA approval for thyroid eye disease. AstraZeneca partnered with insitro for AI-driven drug discovery in MASH and cardiomyopathies. The FDA launched a Rare Disease Framework Initiative to improve drug development for rare diseases. Gilead and Vir Biotechnology agreed to a $1.87 billion collaboration for masked T-cell engagers.

pharmexec.com3 min
OCT 19
$LLYMed

Lilly reports positive pediatric ulcerative colitis trial data

Eli Lilly (NYSE:LLY) reported that its drug Omvoh met the primary endpoint in a Phase 3 study for pediatric ulcerative colitis. The SHINE-2 study showed 81% of patients achieved clinical response at Week 12, with 50% of responders in clinical remission at Week 52. The company plans to submit the data to global regulators for potential label expansion. Omvoh is already approved for adults in 47 countries.

investing.com2 min